Skip to content

Newsroom

Connect with trending topics, events, the industry's best thinkers, news and information.

12/10/2019

Wyckoff Heights Medical Center goes live with Sunrise EHR

Sunrise™ Acute Care, Sunrise™ Revenue Cycle, Sunrise™ Radiology, Sunrise™ HIM Sunrise™ Pharmacy now deployed, as well Allscripts patient engagement platform, FollowMyHealth®; extends and expands Managed Services engagement

CHICAGO–(BUSINESS WIRE)–Dec. 10, 2019–
Allscripts Healthcare Solutions (NASDAQ: MDRX) today announced that client Wyckoff Heights Medical Center is now live on its Sunrise™ platform, which includes Sunrise™ Acute Care, Sunrise Revenue Cycle, Sunrise™ Radiology, Sunrise™ HIM and Sunrise™ Pharmacy as well as Allscripts patient engagement platform, FollowMyHealth®.

Wyckoff Heights Medical Center provides care with kindness. More than 250,000 patient visits for acute, emergency, and surgical services and ambulatory care at locations on the border of Brooklyn and Queens, New York. The organization uses the integrated suite of Allscripts Sunrise solutions which supports the transition to value-based care and to improve clinical decision support. The medical center also recently purchased CarePort™, Allscripts care coordination suite of solutions to help ensure smooth transitions of care across the entire care continuum.

“We selected the Sunrise comprehensive platform to help us drive better care delivery while promoting high levels of patient satisfaction and lowered clinician burnout,” says Ramon Rodriguez, President and CEO of Wyckoff Heights Medical Center. “Our partnership with Allscripts has proved successful and we look forward to seeing results across our entire system. No transition between platforms is without challenges and ours have benefited from the commitment of our Wyckoff staff and the excellent support of the Allscripts crew of onsite advisors. As a customer, I am very satisfied with Allscripts commitment to our needs for customization and on-site learning.”

Used by many of the leading hospitals and health systems in the world, Sunrise is a highly configurable solution that offers clinician-specific workflows that help drive adoption of clinical decision support that leads to improved outcomes. Wyckoff Heights Medical Center is Allscripts first client in New York State to go live on the entire Sunrise™ Financial Manager platform, which will enable the organization to meet the applicable New York state regulatory requirements.

“With the Sunrise suite of solutions, Wyckoff Heights Medical Center has put the organization, its clinicians and, most importantly, its patients in a great position for significantly improved outcomes,” CEO Paul Black says. “Our partnership will continue to yield great results for the Wyckoff Heights community.”

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Source: Allscripts Healthcare Solutions

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Tom Lynch

312-386-6765

Tom.Lynch@allscripts.com

12/05/2019

Allscripts Announces Pricing of $200 Million Convertible Senior Notes Offering

CHICAGO–(BUSINESS WIRE)–Dec. 5, 2019–
Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (“Allscripts”) today announced the pricing of its previously disclosed private offering of $200 million aggregate principal amount of its 0.875% convertible senior notes due 2027 (the “notes”). Allscripts has also granted the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $30 million aggregate principal amount of the notes. The notes are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering and sale of the notes to the initial purchasers is expected to close on December 9, 2019, subject to customary closing conditions.

The notes are senior, unsecured obligations of Allscripts and bear interest at a rate of 0.875% per year, payable semiannually in arrears on January 1 and July 1 of each year, commencing on July 1, 2020. The notes will be convertible at the option of the holders only in certain circumstances and during certain periods. Conversions of the notes may be settled in cash, shares of Allscripts’ common stock, or a combination of cash and shares of Allscripts’ common stock, at Allscripts’ election. Allscripts will not have the right to redeem the notes prior to maturity. The notes will mature on January 1, 2027, unless earlier repurchased or converted in accordance with their terms prior to such date. The initial conversion rate for the notes will be 75.0962 shares of Allscripts’ common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $13.32 per share of Allscripts’ common stock. The initial conversion price of the notes represents a premium of approximately 32.5% to the $10.05 per share last reported sale price of Allscripts’ common stock on December 4, 2019.

Allscripts estimates that the net proceeds from the offering will be approximately $195.0 million (assuming no exercise of the initial purchasers’ option to purchase additional notes), after deducting the initial purchasers’ discount but before estimated offering expenses. Allscripts intends to use $15.8 million of the net proceeds to pay the cost of capped call transactions described below, and Allscripts expects to use the remaining net proceeds to repay outstanding borrowings under its senior secured revolving credit facility.

In connection with the pricing of the notes, Allscripts entered into privately negotiated capped call transactions with JPMorgan Chase Bank, National Association, Wells Fargo Bank, National Association, Bank of America, N.A. and Deutsche Bank AG, London Branch (the “option counterparties”). The capped call transactions are expected generally to reduce the potential dilution to Allscripts’ common stock upon any conversion of notes and/or offset any cash payments Allscripts is required to make in excess of the principal amount of the converted notes, as the case may be, in the event that the market price of Allscripts’ common stock is greater than the strike price of the capped call transactions (which initially corresponds to the initial conversion price of the notes and is subject to certain adjustments under the terms of the capped call transactions), with such reduction and/or offset subject to a cap based on the cap price of the capped call transactions. The cap price of the capped call transactions is initially $17.5875 per share, representing a premium of 75% above the last reported sale price of $10.05 per share of Allscripts’ common stock on December 4, 2019, and is subject to certain adjustments under the terms of the capped call transactions. If the initial purchasers exercise their option to purchase additional notes, Allscripts intends to enter into one or more additional capped call transactions with the option counterparties.

Allscripts expects that in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to Allscripts’ common stock and/or purchase shares of Allscripts’ common stock concurrently with, or shortly after, the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Allscripts’ common stock or the notes at that time. In addition, Allscripts expects that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivative transactions with respect to Allscripts’ common stock and/or purchasing or selling shares of Allscripts’ common stock or other securities of Allscripts in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so during any observation period relating to a conversion of the notes). This activity could also cause or avoid an increase or a decrease in the market price of Allscripts’ common stock or the notes, which could affect the ability of noteholders to convert the notes and, to the extent the activity occurs during any observation period related to a conversion of the notes, could affect the number of shares and the value of the consideration that noteholders will receive upon conversion of the notes.

Neither the notes nor the shares of Allscripts’ common stock issuable upon conversion of the notes, if any, nor the capped call transactions have been, nor will be, registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

This press release is not an offer to sell, or a solicitation of an offer to purchase, any securities of Allscripts. It is issued pursuant to Rule 135c under the Securities Act.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, expectations regarding the notes offering and capped call transactions, the closing of the notes offering, the actions of the option counterparties with respect to the capped call transactions, and Allscripts’ anticipated use of net offering proceeds. These forward-looking statements are based on the current assumptions, expectations and beliefs of Allscripts’ management, only speak as of the date that they are made and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” and similar terms. Actual results could differ significantly from those set forth in the forward-looking statements and reported results should not be considered an indication of future performance. Certain factors that could cause Allscripts’ actual results to differ materially from those described in the forward-looking statements include, but are not limited to: risks related to market and other general economic conditions, Allscripts’ ability to satisfy the closing conditions required for the consummation of the notes offering and the capped call transactions, the final outcome of the criminal and civil investigations by the Department of Justice (the “DOJ”) involving Practice Fusion, Inc. (“Practice Fusion), including our ability to negotiate final settlement agreements with the DOJ and the terms of such agreements; potential additional investigations and proceedings from governmental entities or third parties other than the DOJ related to the same or similar conduct underlying the DOJ’s investigations into Practice Fusion’s business practices; the expected financial results of businesses acquired by us, including the McKesson Corporations Enterprise Information Solutions (“EIS”) portfolio (the “EIS Business”), the NantHealth, Inc. (“NantHealth”) provider/patient solutions business, Practice Fusion and Health Grid Holding Company (“Health Grid”); the successful integration of businesses recently acquired by us; the anticipated and unanticipated expenses and liabilities related to the EIS Business, the NantHealth provider/patient solutions business, Practice Fusion and HealthGrid, including the civil investigation by the U.S. Attorney’s Office involving our EIS Business; security breaches resulting in unauthorized access to our or our clients’ computer systems or data, including denial-of-services, ransomware or other Internet-based attacks; Allscripts’ failure to compete successfully; consolidation in Allscripts’ industry; current and future laws, regulations and industry initiatives; increased government involvement in Allscripts’ industry; the failure of markets in which Allscripts operates to develop as quickly as expected; Allscripts’ or its customers’ failure to see the benefits of government programs; changes in interoperability or other regulatory standards; the effects of the realignment of Allscripts’ sales, services and support organizations; market acceptance of Allscripts’ products and services; the unpredictability of the sales and implementation cycles for Allscripts’ products and services; Allscripts’ ability to manage future growth; Allscripts’ ability to introduce new products and services; Allscripts’ ability to establish and maintain strategic relationships; risks related to the acquisition of new businesses or technologies; the performance of Allscripts’ products; Allscripts’ ability to protect its intellectual property rights; the outcome of legal proceedings involving Allscripts; Allscripts’ ability to hire, retain and motivate key personnel; performance by Allscripts’ content and service providers; liability for use of content; price reductions; Allscripts’ ability to license and integrate third party technologies; Allscripts’ ability to maintain or expand its business with existing customers; risks related to international operations; changes in tax rates or laws; business disruptions; Allscripts’ ability to maintain proper and effective internal controls; and asset and long-term investment impairment charges. Additional information about these and other risks, uncertainties, and factors affecting Allscripts’ business is contained in Allscripts’ filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in the Allscripts Annual Report on Form 10-K for 2018, subsequent Quarterly Reports on Form 10-Q and other public filings with the SEC. Allscripts does not undertake to update forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes in its business, financial condition or operating results over time.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Source: Allscripts Healthcare Solutions, Inc.

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Tom Lynch

312-386-6765

Tom.Lynch@allscripts.com

12/03/2019

Allscripts Announces $200 Million Convertible Senior Notes Offering

CHICAGO–(BUSINESS WIRE)–Dec. 3, 2019–
Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (“Allscripts”) today announced the commencement of a private offering of $200 million aggregate principal amount of its convertible senior notes due 2027 (the “notes”), subject to market and other conditions. Allscripts also expects to grant the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $30 million aggregate principal amount of the notes. The notes will be offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

The notes will be senior, unsecured obligations of Allscripts, and interest on the notes will be payable semiannually in arrears. The notes will be convertible at the option of the holders only in certain circumstances and during certain periods. Conversions of the notes may be settled in cash, shares of Allscripts’ common stock, or a combination of cash and shares of Allscripts’ common stock, at Allscripts’ election. Allscripts will not have the right to redeem the notes prior to maturity. The notes are expected to mature on January 1, 2027, unless earlier repurchased or converted in accordance with their terms prior to such date. The interest rate, conversion rate and certain other terms of the notes will be determined by negotiations between Allscripts and the initial purchasers.

Allscripts expects to use a portion of the net proceeds from the offering to pay the cost of capped call transactions described below, and Allscripts expects to use the remaining net proceeds to repay outstanding borrowings under its senior secured revolving credit facility.

In connection with the pricing of the notes, Allscripts intends to enter into one or more privately negotiated capped call transactions with certain of the initial purchasers and/or their respective affiliates (the “option counterparties”). The capped call transactions are expected generally to reduce the potential dilution to Allscripts’ common stock upon any conversion of notes and/or offset any cash payments Allscripts is required to make in excess of the principal amount of the converted notes, as the case may be, in the event that the market price of Allscripts’ common stock is greater than the strike price of the capped call transactions (which will initially correspond to the initial conversion price of the notes and is subject to certain adjustments under the terms of the capped call transactions), with such reduction and/or offset subject to a cap based on the cap price of the capped call transactions. If the initial purchasers exercise their option to purchase additional notes, Allscripts intends to enter into one or more additional capped call transactions with the option counterparties.

Allscripts expects that in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to Allscripts’ common stock and/or purchase shares of Allscripts’ common stock concurrently with, or shortly after, the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Allscripts’ common stock or the notes at that time. In addition, Allscripts expects that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivative transactions with respect to Allscripts’ common stock and/or purchasing or selling shares of Allscripts’ common stock or other securities of Allscripts in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so during any observation period relating to a conversion of the notes). This activity could also cause or avoid an increase or a decrease in the market price of Allscripts’ common stock or the notes, which could affect the ability of noteholders to convert the notes and, to the extent the activity occurs during any observation period related to a conversion of the notes, could affect the number of shares and the value of the consideration that noteholders will receive upon conversion of the notes.

Pursuant to Allscripts’ publicly announced stock repurchase program, Allscripts opportunistically purchases shares of its common stock and may, in compliance with the provisions of Rule 10b-18 under the Securities Exchange Act of 1934, as amended, purchase shares of Allscripts’ common stock pursuant to open market transactions prior to the pricing of this offering. This activity could increase (or reduce the size of any decrease in) the market price of Allscripts’ common stock at that time and/or the conversion price of the notes.

Neither the notes nor the shares of Allscripts’ common stock issuable upon conversion of the notes, if any, nor the capped call transactions have been, nor will be, registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

This press release is not an offer to sell, or a solicitation of an offer to purchase, any securities of Allscripts. It is issued pursuant to Rule 135c under the Securities Act.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, expectations regarding the notes offering and capped call transactions, the anticipated principal amount of securities to be sold, the actions of the option counterparties with respect to the capped call transactions, the final terms of the offering and Allscripts’ anticipated use of net offering proceeds. These forward-looking statements are based on the current assumptions, expectations and beliefs of Allscripts’ management, only speak as of the date that they are made and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” and similar terms. Actual results could differ significantly from those set forth in the forward-looking statements and reported results should not be considered an indication of future performance. Certain factors that could cause Allscripts’ actual results to differ materially from those described in the forward-looking statements include, but are not limited to: risks related to market and other general economic conditions, Allscripts’ ability to satisfy the closing conditions required for the consummation of the notes offering and the capped call transactions, the final outcome of the criminal and civil investigations by the Department of Justice (the “DOJ”) involving Practice Fusion, Inc. (“Practice Fusion), including our ability to negotiate final settlement agreements with the DOJ and the terms of such agreements; potential additional investigations and proceedings from governmental entities or third parties other than the DOJ related to the same or similar conduct underlying the DOJ’s investigations into Practice Fusion’s business practices; the expected financial results of businesses acquired by us, including the McKesson Corporations Enterprise Information Solutions (“EIS”) portfolio (the “EIS Business”), the NantHealth, Inc. (“NantHealth”) provider/patient solutions business, Practice Fusion and Health Grid Holding Company (“Health Grid”); the successful integration of businesses recently acquired by us; the anticipated and unanticipated expenses and liabilities related to the EIS Business, the NantHealth provider/patient solutions business, Practice Fusion and HealthGrid, including the civil investigation by the U.S. Attorney’s Office involving our EIS Business; security breaches resulting in unauthorized access to our or our clients’ computer systems or data, including denial-of-services, ransomware or other Internet-based attacks; Allscripts’ failure to compete successfully; consolidation in Allscripts’ industry; current and future laws, regulations and industry initiatives; increased government involvement in Allscripts’ industry; the failure of markets in which Allscripts operates to develop as quickly as expected; Allscripts’ or its customers’ failure to see the benefits of government programs; changes in interoperability or other regulatory standards; the effects of the realignment of Allscripts’ sales, services and support organizations; market acceptance of Allscripts’ products and services; the unpredictability of the sales and implementation cycles for Allscripts’ products and services; Allscripts’ ability to manage future growth; Allscripts’ ability to introduce new products and services; Allscripts’ ability to establish and maintain strategic relationships; risks related to the acquisition of new businesses or technologies; the performance of Allscripts’ products; Allscripts’ ability to protect its intellectual property rights; the outcome of legal proceedings involving Allscripts; Allscripts’ ability to hire, retain and motivate key personnel; performance by Allscripts’ content and service providers; liability for use of content; price reductions; Allscripts’ ability to license and integrate third party technologies; Allscripts’ ability to maintain or expand its business with existing customers; risks related to international operations; changes in tax rates or laws; business disruptions; Allscripts’ ability to maintain proper and effective internal controls; and asset and long-term investment impairment charges. Additional information about these and other risks, uncertainties, and factors affecting Allscripts’ business is contained in Allscripts’ filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in the Allscripts Annual Report on Form 10-K for 2018, subsequent Quarterly Reports on Form 10-Q and other public filings with the SEC. Allscripts does not undertake to update forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes in its business, financial condition or operating results over time.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Source: Allscripts Healthcare Solutions, Inc.

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Tom Lynch

312-386-6765

Tom.Lynch@allscripts.com

12/03/2019

EPSi Announces Release of Advanced Analytics Offering

New performance improvement analytics content and services

CHICAGO–(BUSINESS WIRE)–Dec. 3, 2019–
EPSi, Allscripts’ (NASDAQ: MDRX) flagship budgeting, planning/forecasting, cost accounting and financial decision support platform, announced a new advanced analytics product and services solution to the marketplace. The Advanced Analytics platform provides “out of the box” business intelligence data visualizations that will enable hospital decision makers to analyze current performance, utilizing EPSi’s flexible data model to incorporate a wide range of clinical, financial and operational data.

“As EPSi has continued to innovate on our flexible platform, we saw the need to offer new business intelligence capabilities to enable our clients to leverage the rich data in our fully integrated database, which can be further enriched through the use of our Data Extender tool to add even more data to patient records, service lines and more,” said Ralph Keiser, CEO of EPSi. “We will now be able to deliver finished analytics packages, including bundled services and maintenance of the content, data mappings, and visualizations that enable our clients to jumpstart their BI efforts with state-of-the-art technology.”

“EPSi recognizes the trending demand for innovative analytics that can elevate the financial literacy of organizations while also distilling the complexity of financial and clinical data into digestible, actionable insights to drive operational excellence and strategic growth,” said Ryan Self, EPSi’s Vice President of Services. “Through our initial work with our Advanced Analytics partners, we have already seen incredible results in how the tool is engaging and uniting executive leadership, operational managers, and clinical leaders to transform culture and operations.”

About EPSi

EPSi is the industry leader in integrated healthcare decision analytics, budgeting, and planning solutions. More than 1015 installed hospitals in the U.S., including nine of the top 10 rated hospitals, 128 IDN systems, 40 global academic facilities, and international healthcare systems rely on EPSi for data-driven insight into managing costs and improving their long-range financial performance. Learn more about EPSi at www.epsi.io.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2019 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Source: Allscripts

Investors:

Stephen Shulstein

312-386-6735

stephen.shulstein@allscripts.com

Media:

Tom Lynch

312-386-6765

tom.lynch@allscripts.com

11/14/2019

San Gorgonio Memorial Hospital selects Allscripts electronic health record suite for community hospitals

CHICAGO–(BUSINESS WIRE)–Nov. 14, 2019–
Allscripts Healthcare Solutions (NASDAQ: MDRX) today announced that San Gorgonio Memorial Hospital selected its electronic health record (EHR) suite SunriseTM Community Care, which is built specifically for community hospitals.

Sunrise Community Care is an integrated EHR as a service, providing community hospitals a modern, cloud-based EHR to fit the needs of community hospitals that are under 100 beds. This Azure-hosted, single platform EHR is an end-to-end offering with clinical, financial and ambulatory content to help organizations run smoothly and achieve operational and financial success.

San Gorgonio Memorial Hospital offers a variety of high-quality, personalized healthcare services. The hospital serves a very diverse population and provides healthcare for each patient, addressing and answering patients’ needs individually as valued members of the community. San Gorgonio Memorial Hospital ensures the local availability of quality, primary, community healthcare.

“We chose Sunrise Community Care due to it being built especially for the unique challenges community hospitals face,” said Steve Barron, CEO, San Gorgonio Memorial Hospital. “We believe Allscripts and the power of Sunrise Community Care will provide us with the tools and partnership needed to deliver coordinated care across settings—all while providing the best possible patient care.”

The comprehensive EHR as a service includes managed services, software and maintenance, plus regular upgrades in order to keep features and content up to date. Because the EHR is hosted in Microsoft Azure, there is overall improved cost of ownership and shorter implementation times compared to a traditional on-premise implementation. This solution can relieve administrators and clinicians from the burden of configuring an EHR by delivering out-of-the-box, evidenced-based, standardized workflows Allscripts clinicians and usability experts have developed.

“Sunrise Community Care is designed to help meet the unique clinical and financial needs of community hospitals, with a single patient record across the enterprise, enabling their teams to provide safer, more informed patient care,” said Nicole Faucher, Allscripts Vice President, Client Development. “This solution will help San Gorgonio Memorial Hospital improve outcomes, increase patient satisfaction and decrease clinician burnout.”

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Source: Allscripts

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Tom Lynch

312-386-6765

Tom.Lynch@allscripts.com

11/11/2019

Pulse8 Presenting as a Panelist on Provider-Health Plan Relationships During the RISE Risk Adjustment Forum in Scottsdale, AZ

CHICAGO–(BUSINESS WIRE)–Nov. 11, 2019–
In its 14th year, the annual RISE Risk Adjustment Forum acts as a resource for health professionals seeking expert knowledge and continuous improvements to risk adjustment programs from experienced industry specialists, including Pulse8, which is part of Veradigm™, an Allscripts (NASDAQ: MDRX) business unit.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191111005132/en/

This year’s forum will include Pulse8’s Caralyn Maerz, Director of Provider Engagement, as a panelist to discuss leveling up your provider-health plan relationships on Wednesday, November 13th, from 11:30am – 12:30pm MST at the Fairmont Scottsdale Princess in Scottsdale, Arizona.

During this panel, attendees will learn how to:

  • Consider new and innovative ways to fight off provider and member fatigue and come away with new ideas to jointly improve member engagement and patient care
  • Recognize opportunities to collaborate to optimize workflows on both sides to minimize potential abrasion
  • Discuss the impact of acquisitions and consolidations on risk adjustment, and compile strategies to marry operations and workflows

“I am privileged to be speaking on a panel alongside industry leaders spanning from risk-adjustment experts to provider educators and even medical professors,” stated Caralyn Maerz, Pulse8’s Director of Provider Engagement. “Not only will I have an opportunity to educate on my individual experience in the field regarding best practices to engage providers, but I will also be sharing a stage with experts from all avenues of provider interaction who I can learn from as well.”

Attendees will have an opportunity to visit Pulse8 in Booth #1 to speak with Caralyn and other key members of the Pulse8 team. To schedule a meeting or demo, please contact info@Pulse8.com.

About Pulse8

Pulse8, a Veradigm™ brand, is a Healthcare Analytics and Technology Company delivering complete visibility into the efficacy of your Risk Adjustment, Quality, and Pharmacy Benefit Management programs. We enable health plans and providers to eliminate waste and achieve the greatest financial impact in the Medicare Advantage, Medicaid, and ACA Commercial markets as well as with Value-Based Payment models for Medicare. Our advanced analytic methodologies and flexible business intelligence tools offer real-time visibility into member behavior and provider performance. Pulse8’s Illumin8 Active Intelligence™ platform offers a suite of uniquely pragmatic solutions that are powered by our patent-pending Dynamic Intervention Planning to deliver the most cost-effective and appropriate interventions for closing gaps in documentation, coding, and quality. For more company information or to schedule a demo, please contact info@Pulse8.com.

About Veradigm™

Veradigm is an integrated data systems and services business that combines data-driven clinical insights with actionable tools for clinical workflow, research, analytics, and media. Our solutions are designed to help key healthcare stakeholders to improve the quality, efficiency, and value of healthcare delivery – from biopharma to health plans, healthcare providers, health technology partners, and most importantly, the patients they serve. We are dedicated to simplifying the complicated healthcare system with next-generation healthcare solutions. That is how we are transforming health, insightfully. To learn more, visit www.veradigmhealth.com. Veradigm™ is a business unit of Allscripts.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2019 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

About RISE (Resource Initiative and Society for Education)

RISE is the first national association totally dedicated to enabling healthcare professionals working in organizations and aspiring to meet the challenges of the emerging landscape of accountable care and health care reform. We strive to serve our members on four fronts: Education, Industry Intelligence, Networking and Career Development.

Source: Allscripts

Investors:

Stephen Shulstein

312-386-6735

stephen.shulstein@allscripts.com

Media:

Tom Lynch

312-386-6765

tom.lynch@allscripts.com

 

11/04/2019

Allscripts Announces Third Quarter 2019 Results
  • Strong third quarter bookings of $236 million, up 19% year-over-year
  • GAAP EPS ($0.03); 6% year-over-year growth in non-GAAP diluted EPS to $0.17
  • Extended Allscripts Sunrise platform with Northwell Health through 2027
  • Repurchased $46 million of stock in the third quarter

CHICAGO–(BUSINESS WIRE)–Nov. 4, 2019– Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allscripts) announced its financial results for the three and nine months ended September 30, 2019.

Third Quarter Financial Highlights

Bookings(1) were $236 million in the third quarter of 2019. This result compares with $198 million in the third quarter of 2018. Contract revenue backlog totaled $3.9 billion as of September 30, 2019.

Third quarter 2019 GAAP revenue was $444 million, up 3 percent year-over-year. Third quarter 2019 non-GAAP revenue totaled $445 million, up 1 percent year-over-year.

On a GAAP basis in the third quarter of 2019, total operating expenses were $172 million, or a 3 percent decrease year-over-year. Non-GAAP operating expenses totaled $148 million, or a 1 percent decrease year-over-year. Additionally, the company recorded $16 million of transaction, legal and other costs in the third quarter of 2019. This compares with $14 million of such costs in the third quarter of 2018.

GAAP net loss in the third quarter of 2019 totaled ($6) million compared with net loss of ($36) million in the third quarter of 2018. Non-GAAP net income in the third quarter of 2019 totaled $28 million compared with $29 million in the third quarter of 2018.

GAAP loss per share in the third quarter of 2019 was ($0.03), compared with loss per share of ($0.20) in the third quarter of 2018. Non-GAAP diluted earnings per share in the third quarter of 2019 were $0.17 compared with $0.16 in the third quarter of 2018.

Adjusted EBITDA totaled $74 million in the third quarter of 2019, compared with $78 million in the third quarter of 2018.

Stock repurchases totaled $46 million in the third quarter of 2019.

“Our third quarter results show continued strength in new bookings, reflecting how our award-winning solutions resonate with both longtime clients as well as those new to Allscripts,” commented Paul M. Black, Chief Executive Officer of Allscripts. “We were proud to extend our Sunrise partnership with our largest client, Northwell Health, and we’re excited to jointly develop the next-generation electronic health record with Northwell. Looking ahead, we believe revenue growth will improve as we benefit from the strategic investments we’ve made and the platforms we’ve created across both our Provider and Veradigm businesses.”

2019 Financial Outlook(2)

Allscripts is revising the following expectations:

  • Full year 2019 non-GAAP earnings per share between $0.67 and $0.70, an increase at the midpoint from the prior outlook of between $0.65 and $0.70

Allscripts is reiterating the following expectations:

  • Full year 2019 bookings(1) between $1,050 million and $1,100 million
  • Fourth quarter 2019 non-GAAP revenue between $460 million and $470 million
 

Conference Call

Allscripts will conduct a conference call today, Monday, November 4th, 2019, at 4:30 PM Eastern Time to discuss its earnings release and other information. Participants may access the conference call via webcast at http://investor.allscripts.com. Participants also may access the conference call by dialing +1 (877) 269-7756 or +1 (201) 689-7817 (international) and requesting Conference ID # 13694490.

A replay of the call will be available approximately two hours after the conclusion of the call, for a period of four weeks, on the Allscripts Investor Relations website or by calling +1 (877) 660-6853 or +1 (201) 612-7415 – Conference ID # 13694490.

Supplemental and non-GAAP financial information is also available at http://investor.allscripts.com.

Footnotes

  1. Bookings have been determined on a continuing operations basis, excluding Netsmart, and reflect the value of executed contracts for software, hardware, client services, private cloud hosting services, outsourcing and other subscription-based services.
  2. In providing financial guidance, the company does not reconcile non-GAAP earnings per share and non-GAAP revenue guidance to the corresponding GAAP financial measures. Allscripts does not provide guidance for the various reconciling items since certain items that impact GAAP net income and GAAP revenue such as acquisition-related deferred revenue adjustments, acquisition-related amortization, asset impairment charges and transaction, legal and other costs, any of which may be significant, are either outside of its control and/or cannot be reasonably predicted. Please see the “Explanation of Non-GAAP Financial Measures” at the end of this press release for detailed information on calculating non-GAAP measures. For a reconciliation of other non-GAAP items, see the non-GAAP financial reconciliation tables in this release (Tables 4, 5, 6 and 7).

NOTE: All percentage changes described within this press release are calculated from full dollar amounts as illustrated in the accompanying financial statements and Allscripts Supplemental Financial Data Workbook, posted on the Investor Relations website. Rounding differences may occur when individually calculating percentages or totals from rounded amounts included within the press release body compared to full dollar amounts in the tables.

About Allscripts

Allscripts (Nasdaq: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

###

© 2019 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including the statements under “2019 Financial Outlook” and statements related to expected benefits of strategic partnerships and investments. These forward-looking statements are based on the current beliefs and expectations of Allscripts management, only speak as of the date that they are made and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” and similar terms. Actual results could differ significantly from those set forth in the forward-looking statements and reported results should not be considered an indication of future performance. Certain factors that could cause Allscripts actual results to differ materially from those described in the forward-looking statements include, but are not limited to: the final outcome of the criminal and civil investigations by the DOJ involving Practice Fusion, including our ability to negotiate final settlement agreements with the DOJ and the terms of such agreements; potential additional investigations and proceedings from governmental entities or third parties other than the DOJ related to the same or similar conduct underlying the DOJ’s investigations into Practice Fusion’s business practices; the expected financial results of businesses acquired by us, including the EIS business, the NantHealth provider/patient solutions business, Practice Fusion and HealthGrid; the successful integration of businesses recently acquired by us; the anticipated and unanticipated expenses and liabilities related to the EIS business, the NantHealth provider/patient solutions business, Practice Fusion and HealthGrid, including the civil investigation by the U.S. Attorney’s Office involving our EIS business; security breaches resulting in unauthorized access to our or our clients’ computer systems or data, including denial-of-services, ransomware or other Internet-based attacks; Allscripts failure to compete successfully; consolidation in Allscripts industry; current and future laws, regulations and industry initiatives; increased government involvement in Allscripts industry; the failure of markets in which Allscripts operates to develop as quickly as expected; Allscripts or its customers’ failure to see the benefits of government programs; changes in interoperability or other regulatory standards; the effects of the realignment of Allscripts sales, services and support organizations; market acceptance of Allscripts products and services; the unpredictability of the sales and implementation cycles for Allscripts products and services; Allscripts ability to manage future growth; Allscripts ability to introduce new products and services; Allscripts ability to establish and maintain strategic relationships; risks related to the acquisition of new businesses or technologies; the performance of Allscripts products; Allscripts ability to protect its intellectual property rights; the outcome of legal proceedings involving Allscripts; Allscripts ability to hire, retain and motivate key personnel; performance by Allscripts content and service providers; liability for use of content; price reductions; Allscripts ability to license and integrate third party technologies; Allscripts ability to maintain or expand its business with existing customers; risks related to international operations; changes in tax rates or laws; business disruptions; Allscripts ability to maintain proper and effective internal controls; and asset and long-term investment impairment charges. Additional information about these and other risks, uncertainties, and factors affecting Allscripts business is contained in Allscripts filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in the most recent Allscripts Annual Report on Form 10-K and subsequent Form 10-Qs. Allscripts does not undertake to update forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes in its business, financial condition or operating results over time.

 
Table 1
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Balance Sheets
(In millions)
(Unaudited)
             
     

September 30,

   

December 31,

   

2019

   

2018

ASSETS            
Current assets:            
Cash and cash equivalents    

$129.3

   

$174.2

Restricted cash    

9.4

   

10.6

Accounts receivable, net    

426.6

   

465.3

Contract assets    

65.5

   

66.4

Prepaid expenses and other current assets    

142.8

   

142.5

Total current assets    

773.6

   

859.0

Fixed assets, net    

96.8

   

121.9

Software development costs, net    

236.6

   

209.7

Intangible assets, net    

398.0

   

431.1

Goodwill    

1,387.1

   

1,373.7

Deferred taxes, net    

5.0

   

5.0

Contract assets – long-term    

101.9

   

71.9

Right-of-use assets – operating leases    

103.5

   

0.0

Other assets    

127.4

   

109.2

Total assets    

$3,229.9

   

$3,181.5

             
LIABILITIES AND STOCKHOLDERS’ EQUITY            
Current liabilities:            
Accounts payable    

$101.7

   

$73.2

Accrued expenses    

261.9

   

107.0

Accrued compensation and benefits    

57.5

   

100.1

Income tax payable    

0.0

   

29.6

Deferred revenue    

373.1

   

466.8

Current maturities of long-term debt    

358.6

   

20.1

Current operating lease liabilities    

24.5

   

0.0

Current liabilities attributable to discontinued operations    

0.0

   

0.9

Total current liabilities    

1,177.3

   

797.7

Long-term debt    

554.9

   

647.5

Deferred revenue    

12.1

   

16.0

Deferred taxes, net    

55.3

   

58.5

Long-term operating lease liabilities    

100.1

   

0.0

Other liabilities    

49.1

   

81.4

Total liabilities    

1,948.8

   

1,601.1

Total Allscripts Healthcare Solutions, Inc.’s stockholders’ equity    

1,281.1

   

1,551.1

Non-controlling interest    

0.0

   

29.3

Total stockholders’ equity    

1,281.1

   

1,580.4

Total liabilities and stockholders’ equity    

$3,229.9

   

$3,181.5

 
Table 2
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Statements of Operations
(In millions, except per share amounts)
(Unaudited)
                         
     

Three Months Ended September 30,

   

Nine Months Ended September 30,

     

2019

   

2018

   

2019

   

2018

Revenue:                        
Software delivery, support and maintenance    

$284.4

   

$274.2

   

$844.9

   

$839.2

Client services    

159.8

   

158.3

   

475.8

   

468.5

Total revenue    

444.2

   

432.5

   

1,320.7

   

1,307.7

Cost of revenue:                        
Software delivery, support and maintenance    

90.4

   

86.8

   

269.9

   

265.8

Client services    

149.2

   

142.1

   

430.8

   

429.4

Amortization of software development and acquisition-related assets (a)    

29.3

   

25.5

   

86.5

   

76.0

Total cost of revenue    

268.9

   

254.4

   

787.2

   

771.2

Gross profit    

175.3

   

178.1

   

533.5

   

536.5

Selling, general and administrative expenses    

101.1

   

108.1

   

306.9

   

351.0

Research and development    

63.9

   

63.0

   

191.6

   

202.3

Asset impairment charges    

0.2

   

0.0

   

4.0

   

30.1

Amortization of intangible and acquisition-related assets    

6.9

   

6.6

   

20.4

   

19.6

Income (loss) from operations    

3.2

   

0.4

   

10.6

   

(66.5)

Interest expense and other, net (b)    

(10.0)

   

(13.9)

   

(175.1)

   

(37.6)

Gain (loss) on sale of business, net    

0.0

   

0.0

   

0.0

   

172.3

Recovery (impairment) on long-term investments    

0.0

   

0.0

   

1.0

   

(15.5)

Equity in net income (loss) of unconsolidated investments    

0.3

   

(0.4)

   

0.5

   

0.4

Income (loss) before income taxes    

(6.5)

   

(13.9)

   

(163.0)

   

53.1

Income tax (provision) benefit    

0.8

   

1.8

   

(0.6)

   

(5.8)

Income (loss) from continuing operations, net of tax    

(5.7)

   

(12.1)

   

(163.6)

   

47.3

Income (loss) from discontinued operations    

0.0

   

(13.8)

   

0.0

   

(32.9)

Income tax effect on discontinued operations    

0.0

   

2.1

   

0.0

   

7.5

Income (loss) from discontinued operations, net of tax    

0.0

   

(11.7)

   

0.0

   

(25.4)

Net income (loss)    

(5.7)

   

(23.8)

   

(163.6)

   

21.9

Net (income) loss attributable to non-controlling interest    

0.0

   

0.0

   

0.4

   

3.5

Accretion of redemption preference on redeemable convertible
non-controlling interest – discontinued operations
   

0.0

   

(12.1)

   

0.0

   

(36.4)

Net Income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders    

($5.7)

   

($35.9)

   

($163.2)

   

($11.0)

                         
Income (loss) from continuing operations per share – basic    

($0.03)

   

($0.07)

   

($0.97)

   

$0.28

Income (loss) from discontinued operations per share – basic    

$0.00

   

($0.13)

   

$0.00

   

($0.34)

Income (loss) earnings per share – basic    

($0.03)

   

($0.20)

   

($0.97)

   

($0.06)

                         
Income (loss) from continuing operations per share – diluted    

($0.03)

   

($0.07)

   

($0.97)

   

$0.28

Income (loss) from discontinued operations per share – diluted    

$0.00

   

($0.13)

   

$0.00

   

($0.34)

Income (loss) earnings per share – diluted    

($0.03)

   

($0.20)

   

($0.97)

   

($0.06)

                         
Weighted average common shares outstanding:                        
Basic    

166.4

   

174.6

   

167.6

   

176.9

Diluted    

166.4

   

174.6

   

167.6

   

176.9

                         
     

Three Months Ended September 30,

   

Nine Months Ended September 30,

     

2019

   

2018

   

2019

   

2018

                         
(a) Amortization of software development and acquisition-related assets includes:                        
Amortization of capitalized software development costs    

$20.1

   

$15.9

   

$59.3

   

$47.0

Amortization of acquisition-related intangible assets    

9.2

   

9.6

   

27.2

   

29.0

     

$29.3

   

$25.5

   

$86.5

   

$76.0

                         
(b) Interest expense and other, net are comprised of the following for the periods presented:  
                         
Non-cash charges to interest expense    

$3.4

   

$3.2

   

$10.0

   

$9.5

Interest expense    

6.7

   

9.4

   

19.3

   

25.4

Amortization of discounts and debt issuance costs    

0.7

   

0.7

   

2.1

   

2.1

Other (income) loss, net    

(0.8)

   

0.6

   

143.7

   

0.6

Total interest expense and other, net    

$10.0

   

$13.9

   

$175.1

   

$37.6

 
Table 3
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Statements of Cash Flows
(In millions)
(Unaudited)
                         
     

Three Months Ended September 30,

   

Nine Months Ended September 30,

     

2019

   

2018

   

2019

   

2018

Cash flows from operating activities:                        
Net income (loss)    

($5.7)

   

($23.8)

   

($163.6)

   

$21.9

Less: Income(loss) from discontinued operations    

0.0

   

(11.7)

   

0.0

   

(25.4)

Income (loss) from continuing operations    

($5.7)

   

($12.1)

   

($163.6)

   

$47.3

Non-cash adjustments to net income (loss):                        
Depreciation and amortization    

51.7

   

47.8

   

152.3

   

143.0

Operating right-to-use asset amortization    

5.7

   

0.0

   

16.7

   

0.0

Stock-based compensation expense    

7.8

   

8.6

   

29.6

   

25.8

Asset impairment charges    

0.2

   

0.0

   

4.0

   

30.1

Impairment (recovery) of long-term investments    

0.0

   

0.0

   

(1.0)

   

15.5

(Gain) loss on sale of businesses, net    

0.0

   

0.0

   

0.0

   

(172.3)

Other, net    

(1.3)

   

(3.4)

   

(1.0)

   

4.6

Total non-cash adjustments to net income (loss)    

64.1

   

53.0

   

200.6

   

46.7

Cash impact of changes in operating assets and liabilities    

(22.6)

   

(37.2)

   

26.9

   

(28.8)

Net cash provided by (used in) operating activities – continuing operations    

35.8

   

3.7

   

63.9

   

65.2

Net cash provided by (used in) operating activities – discontinued operations    

0.0

   

11.3

   

(30.0)

   

16.3

Net cash provide by (used in) operating activities    

35.8

   

15.0

   

33.9

   

81.5

Cash flows from investing activities:                        
Capital expenditures    

(4.1)

   

(7.9)

   

(13.5)

   

(21.9)

Capitalized software    

(31.0)

   

(25.8)

   

(86.2)

   

(83.1)

Purchases of equity securities in partner entities, business
acquisitions, net of cash acquired and other investments
   

(17.7)

   

(5.6)

   

(30.6)

   

61.2

Net cash provided by (used in) investing activities – continuing
operations
   

(52.8)

   

(39.3)

   

(130.3)

   

(43.8)

Net cash provided by (used in) investing activities – discontinued operations    

0.0

   

(173.5)

   

0.0

   

(189.5)

Net cash provided by (used in) investing activities    

(52.8)

   

(212.8)

   

(130.3)

   

(233.3)

Cash flows from financing activities:                        
Repurchase of common stock    

(37.1)

   

0.0

   

(102.2)

   

(101.9)

Repurchase of unsettled common stock    

(9.3)

   

0.0

   

(9.3)

   

0.0

Proceeds from sale or issuance of common stock    

0.0

   

1.1

   

0.0

   

1.3

Stock-based compensation-related payments, net    

(0.1)

   

(0.2)

   

(6.8)

   

(8.8)

Credit facilities and capital lease payments, net    

64.2

   

14.9

   

234.1

   

75.5

Other payments    

(9.9)

   

0.0

   

(65.4)

   

(10.2)

Net cash provided by (used in) financing activities – continuing operations    

7.8

   

15.8

   

50.4

   

(44.1)

Net cash provided by (used in) financing activities – discontinued operations    

0.0

   

161.1

   

0.0

   

153.5

Net cash provided by (used in) financing activities    

7.8

   

176.9

   

50.4

   

109.4

Effect of exchange rate changes on cash and cash equivalents    

(0.2)

   

(0.1)

   

(0.1)

   

(0.3)

Net increase (decrease) in cash and cash equivalents    

(9.4)

   

(21.0)

   

(46.1)

   

(42.7)

Cash and cash equivalents, beginning of period    

148.1

   

140.8

   

184.8

   

162.5

Cash and cash equivalents, end of period    

$138.7

   

$119.8

   

$138.7

   

$119.8

Less: Cash and cash equivalents included in current assets attributable to discontinued operations    

0.0

   

(17.8)

   

0.0

   

(17.8)

Cash, cash equivalents and restricted cash, end of period, excluding discontinued operations    

$138.7

   

$102.0

   

$138.7

   

$102.0

 
Table 4
Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per share amounts)
(Unaudited)
                                     
     

Three Months Ended September 30, 2019

   

Three Months Ended September 30, 2018

     

GAAP

   

Non-GAAP
Adjustments (1)

   

Non-GAAP

   

GAAP

   

Non-GAAP
Adjustments (1)

   

Non-GAAP

                                     
Revenue    

$444.2

   

$0.4

   

$444.6

   

$432.5

   

$7.3

   

$439.8

Gross profit    

175.3

   

16.7

   

192.0

   

178.1

   

21.6

   

199.7

Total Operating Expenses    

172.1

   

(24.2)

   

147.9

   

177.7

   

(27.9)

   

149.8

Income (loss) from operations    

3.2

   

40.9

   

44.1

   

0.4

   

49.5

   

49.9

Income (loss) from continuing operations, net of tax, net of non-controlling interest    

($5.7)

   

$34.1

   

$28.4

   

($12.1)

   

$40.7

   

$28.6

                                     
Income (loss) from continuing operations per share – diluted    

($0.03)

         

$0.17

   

($0.07)

         

$0.16

                                     
Effective Tax Rate    

12%

         

24%

   

13%

         

27%

                                     
Weighted average common shares outstanding – diluted    

166.4

         

167.9

   

174.6

         

177.2

                                     
                                     
     

Nine Months Ended September 30, 2019

   

Nine Months Ended September 30, 2018

     

GAAP

   

Non-GAAP
Adjustments (1)

   

Non-GAAP

   

GAAP

   

Non-GAAP
Adjustments (1)

   

Non-GAAP

                                     
Revenue    

$1,320.7

   

$1.5

   

$1,322.2

   

$1,307.7

   

$16.6

   

$1,324.3

Gross profit    

533.5

   

41.4

   

574.9

   

536.5

   

71.5

   

608.0

Total Operating Expenses    

522.9

   

(78.6)

   

444.3

   

603.0

   

(139.3)

   

463.7

Income (loss) from operations    

10.6

   

120.0

   

130.6

   

(66.5)

   

210.8

   

144.3

Income (loss) from continuing operations, net of tax, net of non-controlling interest    

($163.2)

   

$247.2

   

$84.0

   

$50.8

   

$38.6

   

$89.4

                                     
Income (loss) from continuing operations per share – diluted    

($0.97)

         

$0.50

   

$0.28

         

$0.50

                                     
Effective Tax Rate    

0%

         

24%

   

11%

         

27%

                                     
Weighted average common shares outstanding – diluted    

167.6

         

169.1

   

176.9

         

179.3

                                     
(1) Please see table 6 for detail on Non-GAAP adjustments.                                    
 
Table 5
Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information – Adjusted EBITDA
(In millions, except percentages)
(Unaudited)
                         
     

Three Months Ended September 30,

   

Nine Months Ended September 30,

     

2019

   

2018

   

2019

   

2018

Net income (loss) from continuing operations, as reported    

($5.7)

   

($12.1)

   

($163.6)

   

$47.3

Plus:                        
Interest expense and other, net (a)    

5.9

   

10.0

   

18.0

   

26.0

Depreciation and amortization    

51.7

   

47.8

   

152.3

   

143.0

Equity in net (income) loss of unconsolidated investments    

(0.3)

   

0.3

   

(0.5)

   

(0.4)

Tax provision/(benefit)    

(0.8)

   

(1.8)

   

0.6

   

5.8

EBITDA    

$50.8

   

$44.2

   

$6.8

   

$221.7

Plus:                        
Acquisition-related deferred revenue adjustments    

0.4

   

9.5

   

1.5

   

23.4

Stock-based compensation expense    

8.5

   

10.0

   

32.5

   

29.9

Transaction, legal and other costs    

14.1

   

14.0

   

177.5

   

78.9

Asset impairment charges    

0.2

   

0.0

   

4.0

   

30.1

(Recovery) impairment on long-term investments    

0.0

   

0.0

   

(1.0)

   

15.5

(Gain) loss on sale of business, net    

0.0

   

0.0

   

0.0

   

(172.3)

Adjusted EBITDA    

$74.0

   

$77.7

   

$221.3

   

$227.2

                         
Adjusted EBITDA margin (b)    

17%

   

18%

   

17%

   

17%

                         
                         
(a) Interest expense and other, net has been adjusted from the amounts presented in the statements of operations in order to remove the amortization of the fair value of the cash conversion option embedded in the 1.25% Cash Convertible Notes and deferred debt issuance costs from interest expense since such amortization is also included in depreciation and amortization.
                         
(b) Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by non-GAAP revenue.
 
Table 6
Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information – Non-GAAP Adjustments
(In millions, except percentages)
(Unaudited)
                           
                           
       

Three Months Ended September 30,

   

Nine Months Ended September 30,

       

2019

   

2018

   

2019

   

2018

                           
  Income (loss) from continuing operations, net of tax and net of non-controlling interest    

($5.7)

   

($12.1)

   

($163.2)

   

$50.8

  Acquisition-related deferred revenue adjustments    

0.4

   

9.5

   

1.5

   

23.4

  Revenue    

0.4

   

7.3

   

1.5

   

16.6

  Gross Profit    

0.4

   

9.5

   

1.5

   

23.4

  Income (loss) from operations    

0.4

   

9.5

   

1.5

   

23.4

  Acquisition-related amortization    

16.1

   

16.1

   

47.6

   

48.6

  Gross Profit    

9.2

   

9.5

   

27.2

   

29.0

  Income (loss) from operations    

16.1

   

16.1

   

47.6

   

48.6

  Stock-based compensation expense    

8.5

   

10.0

   

32.5

   

29.9

  Gross Profit    

1.1

   

1.5

   

4.5

   

5.1

  Income (loss) from operations    

8.5

   

10.0

   

32.5

   

29.9

  Asset impairment charges    

0.2

   

0.0

   

4.0

   

30.1

  Income (loss) from operations    

0.2

   

0.0

   

4.0

   

30.1

  Transaction, legal and other costs    

15.6

   

14.0

   

179.3

   

78.8

  Gross Profit    

6.0

   

1.1

   

8.2

   

14.0

  Income (loss) from operations    

15.7

   

14.0

   

34.4

   

78.8

  Income (loss) from continuing operations before income taxes    

15.6

   

14.0

   

179.3

   

78.8

  Non-cash charges to interest expense and other    

3.4

   

3.8

   

10.0

   

11.0

  (Recovery) impairment on long-term investments    

0.0

   

0.0

   

(1.0)

   

15.5

  (Gain) loss on sale of business, net    

0.0

   

0.0

   

0.0

   

(172.3)

  Equity in net (income) loss of unconsolidated investments    

(0.3)

   

0.3

   

(0.5)

   

(0.4)

  Tax rate alignment    

(9.8)

   

(12.5)

   

(25.9)

   

(26.0)

  Net (income) loss attributable to non-controlling interest    

0.0

   

(0.5)

   

(0.3)

   

0.0

  Non-GAAP income (loss) attributable to Allscripts Healthcare Solutions, Inc.    

$28.4

   

$28.6

   

$84.0

   

$89.4

                           
  Non-GAAP effective tax rate    

24%

   

27%

   

24%

   

27%

                           
  Weighted average shares outstanding – diluted    

167.9

   

177.2

   

169.1

   

179.3

 
Table 7
Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information – Free Cash Flow
(In millions)
(Unaudited)
                         
     

Three Months Ended September 30,

   

Nine Months Ended September 30,

     

2019

   

2018

   

2019

   

2018

Net cash provided by (used in) operating activities – continuing operations    

$35.8

   

$3.7

   

$63.9

   

$65.2

Net cash provided by (used in) operating activities – discontinued operations    

0.0

   

11.3

   

(30.0)

   

16.3

Net cash provided by (used in) operating activities    

35.8

   

15.0

   

33.9

   

81.5

Cash flows from investing activities:                        
Capital expenditures    

(4.1)

   

(7.9)

   

(13.5)

   

(21.9)

Capitalized software    

(31.0)

   

(25.8)

   

(86.2)

   

(83.1)

Cash flows from investing activities – discontinued operations

 

 

0.0

   

(8.7)

   

0.0

   

(22.9)

Free cash flow    

$0.7

   

($27.4)

   

($65.8)

   

($46.4)

 

Explanation of Non-GAAP Financial Measures

Allscripts reports its financial results in accordance with U.S. generally accepted accounting principles, or GAAP. To supplement this information, Allscripts presents in this release non-GAAP revenue, gross profit, gross margin, operating expense, income from operations, Adjusted EBITDA, effective income tax rate, net income and earnings per share, which are considered non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. The definitions of non-GAAP financial measures used throughout this document are presented below:

  • Non-GAAP revenue consists of GAAP revenue, as reported, and adds back recognized deferred revenue from the EIS business, Practice Fusion, HealthGrid, NantHealth’s provider/patient solutions business and non-material consolidated affiliates that is eliminated for GAAP purposes due to purchase accounting adjustments. Reconciliations to GAAP revenue are found in Tables 4 and 6 within this press release.
  • Non-GAAP gross profit consists of GAAP gross profit, as reported, and excludes acquisition-related deferred revenue adjustments, acquisition-related amortization, stock-based compensation expense, non-cash asset impairment charges and transaction, legal and other costs. Non-GAAP gross margin consists of non-GAAP gross profit as a percentage of non-GAAP revenue in the applicable period. Reconciliations to GAAP gross profit are found in Tables 4 and 6 within this press release.
  • Non-GAAP operating expense consists of GAAP selling, general and administrative expenses (SG&A) and research and development expense (R&D), as reported, and excludes transaction, legal and other costs and stock-based compensation expense recorded to SG&A and R&D. Reconciliations to GAAP operating expense are found in Table 4 within this press release.
  • Non-GAAP income from operations consists of GAAP income from operations, as reported, and excludes acquisition-related deferred revenue adjustments, acquisition-related amortization, stock-based compensation expense, non-cash asset impairment charges and transaction, legal and other costs. Reconciliations to GAAP income from operations are found in Tables 4 and 6 within this press release.
  • Adjusted EBITDA is a non-GAAP measure and consists of GAAP net income/(loss), as reported, and adjusts for: acquisition-related deferred revenue adjustments; depreciation and amortization; stock-based compensation expense; transaction, legal and other costs; non-cash asset and long-term investment impairment charges; gain on sale of businesses, net; interest expense and other, net; equity in net earnings of unconsolidated investments; and tax provision (benefit). Reconciliations to GAAP net income/(loss) are found in Table 5 within this press release.
  • Non-GAAP effective income tax rate is based on non-GAAP pre-tax earnings and consists of the statutory federal income tax rate, Allscripts effective state income tax rate and adjustments for permanent differences.
  • Non-GAAP net income consists of GAAP net income/(loss), as reported, and adds back acquisition-related deferred revenue adjustments; acquisition-related amortization; stock-based compensation expense; transaction, legal and other costs; non-cash asset and long-term investment impairment charges; non-cash charges to interest expense and other, asset impairment charges; gain on sale of business, net; and equity in net earnings of unconsolidated investments and the related tax effect of the aforementioned adjustments. Non-GAAP net income also includes a GAAP to non-GAAP tax rate alignment adjustment. Reconciliations to GAAP net income/(loss) are found in Tables 4 and 6 within this press release.
  • Non-GAAP net income attributable to Allscripts Healthcare Solutions, Inc. is a non-GAAP measure and consists of non-GAAP net income, as described above, with an adjustment to reduce non-GAAP net income for the percentage of non-controlling interest outside Allscripts ownership position.
  • Non-GAAP earnings per share consist of non-GAAP net income, as defined above, divided by weighted shares outstanding – diluted during the applicable period.
  • Free cash flow consists of GAAP cash flows provided by operating activities in the applicable period, net of capital expenditures and capitalized software costs, including those incurred by businesses presented as discontinued operations. Reconciliations to GAAP cash flows provided by operating activities are found in Table 7 within this press release.
 

Acquisition-Related Deferred Revenue Adjustments. Deferred revenue adjustments include acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenue acquired in a business acquisition. The fair value of acquired deferred revenue represents an amount equivalent to the estimated cost plus an appropriate profit margin, to perform services related to the acquiree’s software and product support, which assumes a legal obligation to do so, based on the deferred revenue balances as of the acquisition date. Allscripts adds back acquisition-related deferred revenue adjustments for its non-GAAP financial measures because it believes the inclusion of this amount directly correlates to the underlying performance of Allscripts operations.

Acquisition-Related Amortization. Acquisition-related amortization expense is a non-cash expense arising primarily from the acquisition of intangible assets in connection with acquisitions or investments. Allscripts excludes acquisition-related amortization expense from non-GAAP gross profit, non-GAAP operating income, and non-GAAP net income because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods because of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation, and the related amortization expense will recur in future periods.

Stock-Based Compensation Expense. Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards. Allscripts excludes stock-based compensation expense from non-GAAP gross profit, non-GAAP operating income, non-GAAP operating expense, non-GAAP net income and Adjusted EBITDA because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods as a result of the timing and valuation of grants of new stock-based awards, including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods, and such expense will recur in future periods.

Asset impairment charges. Asset impairment charges include (i) the write-off of purchased third-party software as a result of our decision to discontinue several software development projects, (ii) the write-off of acquired technology and value assigned to commercial agreements, and (iii) the write-off of the book value of certain fixed assets that resulted from consolidating business functions and locations.

Transaction, Legal and Other Costs. Transaction, legal and other costs relate to certain legal proceedings and investigations, consulting, severance, incentive compensation and other charges incurred in connection with activities that are considered not reflective of our core business.

Allscripts excludes transaction, legal and other costs, in whole or in part, from non-GAAP gross profit, non-GAAP operating income, non-GAAP operating expense, non-GAAP net income and Adjusted EBITDA because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods.

Non-Cash Charges to Interest Expense and Other. Non-cash charges to interest expense include the amortization of the fair value of the cash conversion option embedded in the 1.25 percent Cash Convertible Notes issued by Allscripts during the second quarter of 2013.

Impairment of Long-Term Investments. Impairment of long-term investments relates to other-than-temporary non-cash impairment charges associated with such investments based on management’s assessment of the likelihood of near-term recovery of the investments’ value. The amounts recorded during the three months ended March 31, 2018 relate to a non-cash impairment charge related to one of our cost-method equity investments and a related note receivable.

 

Gain on sale of business, net. Gain on sale of business, net for the nine months ended September 30, 2018 consists of a gain from the divestitures of our OneContent and Strategic Sourcing businesses, both of which were acquired as part of the EIS transaction during the fourth quarter of 2017. Gain on sale of business, net for the nine months ended September 30, 2018 included a portion of divesture-related loss previously reported as part of transaction-related and other costs during the quarter ended March 31, 2018.

Equity in Net loss (income) of Unconsolidated Investments. Equity in net loss (income) of unconsolidated investments represents Allscripts share of the equity earnings of our investments in third parties accounted for under the equity method, including the amortization of cost basis adjustments.

Tax Rate Alignment. Tax rate alignment aligns the applicable period’s effective tax rate to the expected annual non-GAAP effective tax rate.

Management also believes that non-GAAP revenue, gross profit, gross margin, operating expense, income from operations, effective income tax rate, net income, earnings per share, Adjusted EBITDA, and free cash flow provide useful supplemental information to management and investors regarding the underlying performance of Allscripts business operations. Acquisition accounting adjustments made in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments provided and discussed herein.

Management also uses this information internally for forecasting and budgeting, as it believes that these measures are indicative of core operating results. In addition, management may use non-GAAP gross profit, operating expense, operating income, net income, earnings per share and/or Adjusted EBITDA to measure achievement under Allscripts stock and cash incentive compensation plans. Note, however, that non-GAAP gross profit, operating income, net income earnings per share and Adjusted EBITDA are performance measures only, and they do not provide any measure of cash flow or liquidity. Allscripts considers free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by the business after capital expenditures and capitalized software costs. Free cash flow provides management and investors a valuable measure to determine the quantity of capital generated that can be deployed to create additional shareholder value by a variety of means. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the definitions and reconciliations of non-GAAP financial measures with GAAP financial measures contained within the attached condensed consolidated financial statements.

Source: Allscripts Healthcare Solutions, Inc.

For more information contact:

Investors:
Stephen Shulstein
312-386-6735
stephen.shulstein@allscripts.com

Media:
Tom Lynch
312-386-6765
tom.lynch@allscripts.com

10/21/2019

Allscripts to release third-quarter 2019 financial results November 4

CHICAGO–(BUSINESS WIRE)–Oct. 21, 2019–
Allscripts Healthcare Solutions, Inc. (Nasdaq:MDRX) will report its financial results for the three months ended September 30, 2019, after the close of stock market hours on Monday, November 4, 2019. Allscripts management plans to host a conference call and webcast to discuss the company’s earnings and other information at 4:30 p.m. Eastern Time that same day.

Third-Quarter 2019 Financial Results Call Details

The Allscripts earnings announcement will be distributed immediately after the close of regular stock market hours on November 4, 2019. The announcement will also be available at Allscripts investor relations website.

To listen to the conference call, participants may log onto the Allscripts Investor Relations website. Participants also may access the conference call by dialing (877) 269-7756 or 201-689-7817 and requesting Conference ID #13694490.

A replay of the call will be available approximately two hours after the conclusion of the call, for a period of four weeks, on the Allscripts investor relations website or by calling (877) 660-6853 or (201) 612-7415 – Conference ID # 13694490.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2019 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Source: Allscripts

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Tom Lynch

312-386-6765

Tom.Lynch@allscripts.com

10/15/2019

Northwell Health extends partnership with comprehensive Allscripts Sunrise™ platform through 2027

CHICAGO–(BUSINESS WIRE)–Oct. 15, 2019–
Allscripts Healthcare Solutions (NASDAQ: MDRX) today announced that Northwell Health has extended its engagement with the comprehensive Allscripts Sunrise inpatient platform through December 2027. Sunrise is currently in use at 19 Northwell hospitals.

Northwell Health—New York State’s largest health system, which has been live on Sunrise since 2005—continues to expand the platform’s use as additional Northwell Health facilities come on board. The health system previously extended its Allscripts TouchWorks® EHR agreement in 2018.

“The power of Sunrise drives our system across nearly 20 locations, helping our organization deliver on our mission of improving the health of our communities,” says Northwell CIO John Bosco. “Running successfully on one instance of the EHR proves especially beneficial for ensuring our thousands of clinicians can easily access consistent and comprehensive patient clinical information.”

Used by healthcare organizations across the globe, Sunrise is an integrated electronic health record that connects all aspects of care, including acute, ambulatory, surgical, pharmacy, radiology and laboratory services. Built to enable efficient and safe care, Sunrise is a clinician-friendly, evidence-based single platform with integrated analytics that helps deliver true personalized care. Sunrise supports all core care venues across the enterprise by delivering a single patient record, and features patient-centric capabilities that increase access and convenience.

“Allscripts partnership with our largest client, Northwell Health, has been a great success for the past 15 years. We are honored to continue pursuing our shared vision with such a brilliant thought leader in our industry,” said Allscripts CEO Paul Black. “Northwell is truly passionate about advancing its community’s health. Side by side we will continue to enhance Sunrise and co-develop the next generation of EHR as a new powerful solution, a tool for clinicians not only at Northwell but at other providers and for those they serve. It’s an honor to extend our partnership with Northwell and its visionary leadership.”

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Source: Allscripts

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Tom Lynch

312-386-6765

Tom.Lynch@allscripts.com

10/10/2019

Veradigm Health joins Harvard Pilgrim to develop next phase of FDA’s Sentinel System

 Five-year award signals FDA’s commitment to national program utilizing electronic healthcare data to monitor the safety of FDA-regulated drugs and other medical products 

 CHICAGO–(BUSINESS WIRE)–Oct. 10, 2019–
Veradigm™, an Allscripts (NASDAQ: MDRX) business unit dedicated to simplifying healthcare with data-driven health insights and technologies to help manage cost and improve health outcomes, announced today that its Life Sciences business unit joins the Harvard Pilgrim Healthcare Institute and other collaborating partners to continue to develop the FDA Sentinel System, the largest multisite distributed database in the world dedicated to drug safety. The award focuses on two areas: first, managing the Sentinel Operations Center, which builds upon the Institute’s 10 years of experience developing and operating the Sentinel System; and second, developing a new Sentinel Innovation Center.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005125/en/

According to the FDA, the Operations Center will continue to leverage organizational partnerships in the areas of epidemiology, clinical medicine, pharmacy, statistics, health informatics, data science and network operations, to support post approval safety analyses. The Innovation Center will be focused on developing innovative methods to further advance Sentinel, including exploring novel ways to extract and structure information from electronic health records (EHRs).

As a business unit of Allscripts, one of the world’s largest EHR providers, Veradigm is especially well positioned to help the Harvard Pilgrim team achieve FDA’s objective to better utilize information from EHRs in the next phase of Sentinel development. Veradigm currently offers HealthInsights, the largest deidentified EHR database available for life sciences research (~150m patients) that has been linked to integrated claims for certain research studies. In addition, Veradigm collaborates with healthcare providers to implement point-of-care research programs, engaging patients and prospectively collecting additional data using Allscripts EHR platforms.

“Veradigm is excited to collaborate with Harvard Pilgrim to continue to advance the Sentinel System,” said Tom Langan, Chief Executive Officer for Veradigm. “I believe our position as the Life Sciences-focused business unit of Allscripts enables us to approach the challenge in innovative ways, helping to increase efficiency, responsiveness and the scale of Sentinel.”

 About Veradigm™  

Veradigm is an integrated data systems and services business that combines data-driven clinical insights with actionable tools for clinical workflow, research, analytics, and media. Our solutions are designed to help key healthcare stakeholders to improve the quality, efficiency, and value of healthcare delivery – from biopharma to health plans, healthcare providers, health technology partners, and most importantly, the patients they serve. We are dedicated to simplifying the complicated healthcare system with next-generation healthcare solutions. That is how we are transforming health, insightfully. To learn more, visit www.veradigmhealth.com. Veradigm™ is a business unit of Allscripts.

 About Allscripts 

 Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog. 

© 2019 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Source: Allscripts

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

 
Media:

Tom Lynch

312-386-6765

Tom.Lynch@allscripts.com 

10/01/2019

Northwell, Allscripts to jointly develop next-gen electronic health record

 CHICAGO–(BUSINESS WIRE)–Oct. 1, 2019–
Northwell Health, New York State’s largest health system, and Allscripts (NASDAQ: MDRX) today announced an innovative agreement to create the next-generation electronic health record (EHR). The cloud-based, voice-enabled, artificial intelligence-based EHR will be designed and tested using input from Northwell clinicians, information technology experts and administrators with the goal of ultimately deploying it systemwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191001005126/en/

 

Northwell, Allscripts to jointly develop next-gen electronic health record (Photo: Business Wire)

Northwell, Allscripts to jointly develop next-gen electronic health record (Photo: Business Wire)

 

 

 Chicago, IL-based Allscripts, which specializes in connecting consumers with healthcare providers and payment solutions, will provide the development and systems integration expertise to build the new and improved EHR. The product will optimize the user experience and enhance the delivery of care to improve the experience for both clinicians and patients alike.

“We are excited about the possibilities that this alliance with Allscripts will generate,” said Michael J. Dowling, Northwell Health’s president and chief executive officer. “Coupling Allscripts’ technology expertise with Northwell’s clinical and operational strengths will enable us to create a dynamic, patient-facing tool that will arm clinicians with knowledge to provide exceptional care to our patients.”

Allscripts and Northwell will jointly develop and pilot the new EHR while continuing to support and enhance Allscripts Sunrise™, the EHR platform currently in use at the 19 Northwell hospitals and Allscripts Touchworks™, currently in use at more than 750 outpatient practices that Northwell owns and operates throughout the New York area. Northwell has been using Allscripts’ EHR since 2009 to advance the automation of inpatient and outpatient records in all medical settings across the health system.

“Allscripts partnership with Northwell Health has been successful for many years and, together, we are positioned to develop and launch the electronic health record of tomorrow,” said Paul Black, Allscripts Chief Executive Officer. “By focusing on the needs of both clinicians and patients, this innovative collaboration will help lead the healthcare IT industry into the future.”

 About Northwell Health 

 Northwell Health is New York State’s largest health care provider and private employer, with 23 hospitals, about 750 outpatient facilities and more than 13,600 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 70,000 employees – 16,000-plus nurses and 4,000 employed doctors, including members of Northwell Health Physician Partners – are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We’re training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Graduate Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Twitter, Instagram and LinkedIn.

 About Allscripts 

 Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and The Allscripts Blog.

© 2019 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Source: Allscripts

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

 
Media:

Tom Lynch, Allscripts

312-386-6765

tom.lynch@allscripts.com

 
Jason Molinet, Northwell Health

516-321-6705

jmolinet@northwell.edu 

09/04/2019

Allscripts Outperforms Competitors in New Global EHR Report From Black Book™ Research

Black Book’s Annual State of Global EHR Research names Allscripts top health system EHR vendor in meeting client implementation expectations globally

CHICAGO–(BUSINESS WIRE)–Sep. 4, 2019–
Allscripts (NASDAQ: MDRX) has been ranked number one of 68 named EHR vendors in a Black Book Research user satisfaction survey globally.

The report surveyed 4,056 current EHR users around the globe, providing insight into specific EHR progress and outcomes on vendor experience and client satisfaction. According to 1,490 combined respondents, Allscripts received particularly high marks in the UK, and for the first time was named the top health system EHR vendor in Canada, Australia and New Zealand. Prior to this report, Black Book named the Allscripts Sunrise platform as the top overall inpatient EHR for large hospitals across the United States in 2019. It also has named Allscripts ambulatory EHRs number one among independent physician practices with 26 or more practitioners since 2014.

“Allscripts is one of the leading EHR vendors to make the greatest impact and fastest inroads by confronting the challenges of localizing solutions, acquiring qualified regional support vendors, deposing established incumbents, aligning products to match government requirements and projects and putting in place in-country implementation, project management and local support teams, which all requires significant time and investment,” said Doug Brown, President and CEO of Black Book Research.

The report, conducted Q1 through Q3 2019, includes specific data on several key regions and countries, including Canada, Australia, New Zealand, Mexico, Brazil, Scandinavia, Germany, and Italy; as well as emerging and rapidly expanding EHR markets in South America, China, Singapore, Taiwan, India, Middle East, Central Europe, and African nations. The top-ranked EHR HIT vendors were measured by 18 key performance indicators and rated by outcomes in meeting buyer expectations, meeting forecast budget costs, and meeting or exceeding time and resource allocation goals.

The report’s findings adds to the growing positive momentum Allscripts has harnessed in markets outside the United States, which includes its first-ever deal in the Philippines and Gloucestershire Hospitals NHS Foundation Trust’s selection of Allscripts Sunrise™.

“Allscripts’ clients around the globe are achieving improved outcomes, seeing first-hand the power of our open, integrated solutions,” said Alan Fowles, President Allscripts International. “This report illustrates Allscripts clients’ dedication to their caregivers’ successful patient care through the efficient adoption of our solutions, as well as our commitment to providing world-class platforms that transform the healthcare IT industry.”

“Black Book’s extensive, comprehensive and unparalleled objective methodology makes this recognition a credible indicator of Allscripts expanding global footprint,” Allscripts Chief Executive Officer Paul M. Black said. “We’re proud of the broad base of feedback received from multiple disciplines throughout our global client base demonstrating how we are supporting healthcare organizations around the world to provide high quality and more efficient healthcare.”

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTubeandIt Takes A Community: The Allscripts Blog.

About Black Book™

Black Book Research, a division of Black Book Market Research LLC, provides healthcare IT users, media, investors, analysts, quality minded vendors, and prospective software system buyers, pharmaceutical manufacturers, and other interested sectors of the clinical technology industry with comprehensive comparison data of the industry’s top respected and competitively performing technology vendors. The largest user opinion poll of its kind in healthcare IT, Black Book™ collects over 540,000 viewpoints on information technology and outsourced services vendor performance annually. Black Book was founded in 2002, is internationally recognized for over 15 years of customer satisfaction polling, particularly in technology, services, outsourcing and offshoring industries.

© 2019 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Source: Allscripts

Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

Scroll To Top